Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneus Ltd. ( (AU:CMB) ) has shared an announcement.
Cambium Bio Limited announced the results of its 2025 Annual General Meeting, where all resolutions were carried by poll. However, more than 25% of the votes cast on the 2025 Remuneration Report were against its adoption, marking a ‘first strike’ under section 250U of the Corporations Act 2001. This outcome may have implications for the company’s governance and stakeholder relations.
More about Regeneus Ltd.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on developing innovative biologics for ophthalmology and tissue repair applications. The company’s proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, primarily targeting ophthalmology. Cambium Bio’s lead product candidate, Elate Ocular®, is being developed to address unmet medical needs in treating dry eye disease. Additionally, their stem cell platform, Progenza™, is applied to therapies for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 18,700
Technical Sentiment Signal: Sell
Current Market Cap: A$11.43M
Find detailed analytics on CMB stock on TipRanks’ Stock Analysis page.